Abbott shifts to tricuspid repair
First-look data on Abbott’s tricuspid-focused MitraClip follow-on device are promising, but can TriClip emulate its predecessor’s success?
A delicate balancing act for Immunogen
The group is desperately playing up mirvetuximab, but its future rests with a pair of earlier-stage projects.
A tale of two eyes as Meiragtx sees a clearer path forward than Gensight
As Meiragtx wows investors with its gene therapy for a cause of blindness, continuing lack of clarity around Gensight’s GS010 prompts more questions than answers.
Myovant punished for success
A phase III win for the company’s uterine fibroids candidate fails to calm investor concerns about an expensive launch and a rival with deeper pockets.
Roxadustat safety analysis provokes more questions than answers
Fibrogen tumbles on a confusing safety update for its most advanced project.
Astra and Daiichi lay out their plan for a better Herceptin
The companies’ DS-8201 succeeds in breast cancer patients who had failed Kadcyla, and will go before the regulators later this year.
AAN 2019 – Roche confirms its place in spinal muscular atrophy
A slew of data on spinal muscular atrophy projects over the weekend shows that this tiny market is set for some big competition, with Novartis, Roche and Biogen jostling…
GW sets its sights on Zogenix and a new Epidiolex use
A strong pivotal result should allow the company to broaden Epidiolex’s reach to tuberous sclerosis complex, as long as liver injury risk can be ruled out.
Vistagen tries not to get depressed despite bad omens
A flop in a small depression trial hits Vistagen Therapeutics, but the group insists that all is well ahead of its main event.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.